Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing

被引:41
作者
Zackrisson, AL [1 ]
Lindblom, B
机构
[1] Linkoping Univ, Fac Hlth Sci, Dept Med & Care, Div Clin Pharmacol, SE-58185 Linkoping, Sweden
[2] Natl Board Forens Med, Dept Forens Genet, Linkoping, Sweden
关键词
CYP2D6; pyrosequencing; pharmacogenetics;
D O I
10.1007/s00228-003-0654-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. To develop a single nucleotide polymorphism (SNP) analysis for identification of cytochrome P-450 (CYP)2D6 alleles by pyrosequencing. Methods. Swedish blood donors (n=282) were typed for a partial CYP2D6 genotype comprising the alleles *1 (wild type), *2 (2850C>T), *3 (2549A>del), *4 (1846G>A) and *6 (1707T>del) using polymerase chain reaction (PCR) and pyrosequencing analysis. CYP2D6*5 (CYP2D6 deleted) was identified using an established long multiplex PCR method. Pyrosequencing is a sequencing-by-synthesis method in which a cascade of enzymatic reactions yields detectable light, which is proportional to the incorporated nucleotides. One feature of typing SNPs by pyrosequencing is that each allelic variant will give a unique sequence. These variants can be readily distinguished by pattern recognition software. Results. Of 281 individuals analysed, 24 (8.5%) were found to be poor metabolisers with two non-functional alleles. This is in the range of 7-10%, previously reported for Caucasians. A total of 126 individuals (45%) had one functional and one non-functional allele and 131 individuals (47%) had two functional alleles. Conclusion. Pyrosequencing was found to be a fast and efficient tool for genotyping. The method is robust, reliable, rapid and has high throughput.
引用
收藏
页码:521 / 526
页数:6
相关论文
共 21 条
[1]   Single-nucleotide polymorphism analysis by pyrosequencing [J].
Ahmadian, A ;
Gharizadeh, B ;
Gustafsson, AC ;
Sterky, F ;
Nyrén, P ;
Uhlén, M ;
Lundeberg, J .
ANALYTICAL BIOCHEMISTRY, 2000, 280 (01) :103-110
[2]   Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing [J].
Alderborn, A ;
Kristofferson, A ;
Hammerling, U .
GENOME RESEARCH, 2000, 10 (08) :1249-1258
[3]   Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry [J].
Brosen, K .
THERAPEUTIC DRUG MONITORING, 1996, 18 (04) :393-396
[4]   INTERPRETATION OF A SIMPLE PCR ANALYSIS OF THE CYP2D6(A) AND CYP2DG(B) NULL ALLELES ASSOCIATED WITH THE DEBRISOQUINE SPARTEINE GENETIC-POLYMORPHISM [J].
DOUGLAS, AM ;
ATCHISON, BA ;
SOMOGYI, AA ;
DRUMMER, OH .
PHARMACOGENETICS, 1994, 4 (03) :154-158
[5]  
Eichelbaum M, 1986, Prog Clin Biol Res, V214, P157
[6]  
GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
[7]   GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION [J].
HEIM, M ;
MEYER, UA .
LANCET, 1990, 336 (8714) :529-532
[8]  
Hersberger M, 2000, CLIN CHEM, V46, P1072
[9]   POLYMORPHISMS OF OXIDATION AT CARBON CENTERS OF DRUGS AND THEIR CLINICAL SIGNIFICANCE [J].
IDLE, JR ;
SMITH, RL .
DRUG METABOLISM REVIEWS, 1979, 9 (02) :301-317
[10]  
INGELMANSUNDBER.M, HUMAN CYTOCHROME P45